Fig. 1: KRAS and TP53 co-mutation status as predictive marker for benefit from ICI in lung adenocarcinoma.
From: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
a,b Heidelberg cohort (HD-ICI): prognostic impact of co-mutations status in patients treated with ICI. c,d TCGA cohort (TCGA-LUAD): absence of the prognostic impact of co-mutations status in patients that underwent surgery.
